title: Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes.
abstract: BACKGROUND
  Diabetes mellitus has been linked to cognitive decrement faster than usual. Medical management of diabetes can also interfere with the cognitive skills. The purpose of this study was to evaluate the effects of vildagliptin on cognition, as an add-on to metformin therapy in elderly patients with type 2 diabetes mellitus.
  
  
  METHODS
  This was a prospective and observational investigation conducted in 10 elderly type 2 diabetes mellitus patients who were started treatment with vildagliptin 50 mg twice daily to ongoing metformin. All participants underwent detailed clinical cognitive assessment and neuropsychological testing with mini mental state examination (MMSE) and clock drawing test (CDT), along with measurement of functional parameters at entry and study completion.
  
  
  RESULTS
  Mean follow-up time was 10.9±3.7 months. No subjects reported significant side effects during the study. At follow-up, in accordance with the clinical assessment, neither MMSE nor CDT showed significant changes after addition of vildagliptin to metformin. Basic and instrumental activities of daily living (BADL and IADL), mini nutrition assessment and geriatric depression scale scores also remained unchanged between the two evaluations.
  
  
  CONCLUSIONS
  In this pilot study, addition of vildagliptin to ongoing metformin therapy in elderly with diabetes was accompanied by stable cognitive and functional performance after almost one year of follow-up.
authors.affiliation: Department of Internal Medicine, Gulhane School of Medicine, GATA Ic Hastaliklari B.D., Etlik 06018, Ankara, Turkey. ilkertasci@yahoo.com.
authors.forename: Ilker
authors.initials: I
authors.lastname: Tasci
authors.forename: Mehmet Ilkin
authors.initials: MI
authors.lastname: Naharci
authors.forename: Ergun
authors.initials: E
authors.lastname: Bozoglu
authors.forename: Umut
authors.initials: U
authors.lastname: Safer
authors.forename: Aydogan
authors.initials: A
authors.lastname: Aydogdu
authors.forename: Basak Filiz
authors.initials: BF
authors.lastname: Yilmaz
authors.forename: Gulay
authors.initials: G
authors.lastname: Yilmaz
authors.forename: Huseyin
authors.initials: H
authors.lastname: Doruk
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000368:Aged; D000369:Aged, 80 and over; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008687:Metformin / Q000008:administration & dosage*; D009570:Nitriles / Q000008:administration & dosage*; D011446:Prospective Studies; D011759:Pyrrolidines / Q000008:administration & dosage*; D000077597:Vildagliptin
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D009570:Nitriles; D011759:Pyrrolidines; D008687:Metformin; D000077597:Vildagliptin; D000218:Adamantane